Gastric Cancer (Diagnosis)NCT07517432
The UGIRA International Registry for RAMIG for Gastric Cancer
An observational study of Gastric Cancer (Diagnosis) and Gastrectomy, run by Chinese University of Hong Kong at 1 site in Hong Kong.
Trial summary
Minimally invasive gastrectomy (MIG) has gained in popularity, since it is feasible, safe and oncologically comparable to open gastrectomy, while morbidity and duration of hospitalization are reduced, quality of life is increased, and conversion rate is low. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Gastric Cancer (Diagnosis), Gastrectomy
- How many people
- 200 participants
- Where
- 1 siteHong Kong
- Study dates
- 1 Apr 2021to 31 Mar 2031
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All gastric cancer patients undergoing RAMIG in a center
Who may be able to join
- All gastric cancer patients undergoing RAMIG in a center
Who cannot join
- No
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Shannon Melissa CHAN, MBChB, FRCSEd, FHKAM (Surgery) contact
Hong Kong1 site, 1 recruiting
- Recruiting
The Chinese University of Hong Kong, Shatin, HK
Hong Kong
Shannon Melissa CHAN, MBChB, FRCSEd, FHKAM (Surgery), +852 3505 2956, shannonchan@surgery.cuhk.edu.hk
About this study
Official title: The UGIRA International Registry for Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) for Gastric Cancer
Minimally invasive gastrectomy (MIG) has gained in popularity, since it is feasible, safe and oncologically comparable to open gastrectomy, while morbidity and duration of hospitalization are reduced, quality of life is increased, and conversion rate is low.
However, several challenges are faced during MIG, such as impaired depth perception and limited range of motion of instrument tips. Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) can potentially overcome these challenges, while providing comparable results regarding safety, technical feasibility, morbidity and oncological effectiveness. However, the techniques and outcomes of RAMIG vary in literature, which can partly be explained by lack of uniform definitions of postoperative outcomes that would allow international comparison. Furthermore, RAMIG is technically demanding and therefore associated with a learning curve.
Read more
To facilitate safe and effective implementation of RAMIG worldwide, the learning curve for RAMIG-procedures must be evaluated in detail. A prospective international registry with uniform data collection regarding surgical techniques and postoperative outcomes can provide a platform for multicontinental studies and the monitoring of surgical quality for surgeons who are implementing RAMIG in their center. Therefore, the aim of this study proposal is to expand the Upper Gastrointestinal International Robotic Association (UGIRA) collaboration by creating the UGIRA International Registry for RAMIG. The UGIRA network extends worldwide with members in Europe, Asia, North-America and South-America, therefore representing large-scale practice of RAMIG. The initial specific aims of the registry are to gain insight in surgical techniques and postoperative outcomes of RAMIG worldwide, and to evaluate the learning curve for RAMIG.
Data for this registry is collected prospectively and retrospectively.
Read the detailed description
Gastric cancer is the 3rd most common cause of cancer related deaths worldwide. For resectable gastric cancer, gastrectomy with curative intent combined with an adequate lymphadenectomy results in a 5-year survival rate of 10 - 30%. Survival can be improved by neoadjuvant or perioperative chemotherapy (FLOT-regimen) due to tumor volume reduction resulting in a higher R0-resection rate and due to targeting of (micro)metastases. Although a traditional open approach for gastrectomy is widely performed and provides adequate oncological results, minimally invasive gastrectomy (MIG) is increasingly implemented over the recent years. The aim of MIG is to minimize surgical trauma while achieving non-inferior oncological results and to reduce morbidity in comparison to open gastrectomy (OG).
Meta-analyses have demonstrated decreased postoperative pain, shorter duration of hospitalization, and improved postoperative recovery and quality of life in favour of MIG compared to OG. MIG reduces wound complications and overall complication rate, although no significant difference was found in complication rates for anastomotic leakage or stenosis, ileus, postoperative bleeding, abdominal abscess and postoperative mortality. The number of retrieved lymph nodes, resection radicality and disease free and overall survival are comparable between MIG and OG, although not many studies reported on these outcomes. Even with the operating time for MIG is prolonged by 45 - 49 minutes, intraoperative blood loss is reduced, and the conversion rate is low, these results show that MIG is feasible, safe and oncological comparable to OG. Morbidity and hospital stay are reduced and quality of life increased as well.
Although it has gained in popularity, MIG involves technical challenges such as impaired depth perception, limited range of motion of instruments and an ergonomically suboptimal posture of the surgeon while operating. Robotic assisted surgery can potentially overcome these challenges since it allows for improved dexterity by 3D-visualization for adequate depth perception and by greater range of motion using EndoWrist (Intuitive Surgical, Sunnyvale, CA, USA) with 7° of freedom, 90° articulation and 540° rotation, mimicking articulation of wrist and hand. Furthermore, tremor suppression, 10-fold enlargement and tool handling controlled by the primary surgeon instead of a secondary assisting surgeon contribute to an improved image stability and smooth movements.
These adjustments optimize surgical precision and facilitate anastomotic techniques and suturing. Robot-assisted minimally invasive gastrectomy (RAMIG) is comparable to MIG regarding safety, technical feasibility, intra- and postoperative morbidity and oncological effectiveness. Some studies suggest RAMIG could achieve a more extensive lymphadenectomy and less intraoperative blood loss, although it may prolong operating time and increase costs in comparison to MIG. However, RAMIG is a demanding proficiency for which training is required to acquire adequate robotic skills. While the learning curve for MIG is around 50 - 60 cases, surgeons experienced in MIG may reach proficiency for RAMIG after only 20 - 25 cases. Since complications rates may be higher for surgeons starting with RAMIG, the duration of the learning period should be minimized in order to prevent unnecessary patient harm. However, most studies are retrospective, single-centered, have limited power due to small sample size, and contain heterogeneity in anastomotic techniques and the extent of lymph node dissection. An unknown learning curve may worry surgeons and could restrain them from implementing RAMIG in their hospitals. Therefore, additional research is warranted to investigate this learning period in detail.
Variation in definitions of complications after gastrectomy lead to differences in reported outcomes, which represents a major challenge when comparing results from multiple centers. Uniform definitions should be used in order to adequately compare complications and their impact on outcomes internationally, which could aid in identifying factors in clinical care which could be improved. Currently, there is no widespread consensus on standardized definitions of complications after gastrectomy. Therefore, the Gastrectomy Complications Consensus Group (GCCG) was formed. Standardize definitions have yet to be published. However, an international registry using an online electronic case report form (eCRF) to uniformly collect perioperative outcomes is essential to minimize such variability. Therefore, this study aims to establish such an international RAMIG registry.
The current initiative aims to expand the collaboration of international experts that was previously established with UGIRA by creating a registry for RAMIG that can be used to initiate international studies and to monitor the surgical quality for surgeons implementing RAMIG in new centers. The UGIRA aims to facilitate the effective implementation and furtherance of robotic esophagogastric surgery. In this context, UGIRA already initiated an international registry for RAMIE and defined a structured training pathway that can be used to guide surgeons starting with RAMIE through their implementation phase. With a more intensified collaboration that also focuses on RAMIG, UGIRA aims to facilitate its worldwide implementation and advancement, and to provide an international platform for discussion and to share surgical vision on topics in this area. This existing experience and UGIRA-network can be used to achieve the key initial aims of the RAMIG registry, which are to create an international registry to gain insight in surgical techniques and postoperative outcomes of RAMIG worldwide, and to evaluate the learning curve for RAMIG.
The principal investigators have previously established an international registry for robot-assisted minimally invasive esophagectomy (RAMIE) supported by Intuitive Surgical Inc. In the context of aiming for worldwide collaboration between international experts in robotic esophagogastric surgery, the UMC Utrecht has co-founded the Upper Gastrointestinal International Robotic Association (UGIRA, www.ugira.org), currently chaired by Richard van Hillegersberg. The UGIRA now includes members from Europe, Asia, North- America and South America (Annex 1), and aims to facilitate the effective implementation and furtherance of robotic esophagogastric surgery.
In the UMC Utrecht, the investigators have developed a structured training pathway that can be used to guide surgeons starting with RAMIE through their implementation phase. It is found that applying this structured training pathway can reduce the learning curve for RAMIE substantially from 70 to 24 cases. Furthermore, no differences were observed regarding postoperative morbidity, mortality and oncological outcomes during the learning phase compared to after completing the learning phase.
Based on these studies, it can be concluded that the structured training pathway is a safe and effective strategy to implement RAMIE in new centers. UGIRA is currently working on establishing a structured training pathway for RAMIG, as was previously done for RAMIE.
Data for this registry is collected prospectively and retrospectively.
- Conditions
- Gastric Cancer (Diagnosis), Gastrectomy
- Keywords
- gastric cancer, Gastrectomy
- Medical subject headings
- Stomach Neoplasms, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| All patients undergoing Robot-Assisted Minimally Invasive Gastrectomy. | All patients with gastric cancer, who is about to undergo Robot-Assisted Minimally Invasive Gastrectomy. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Operation Outcome - operating time
Operating time (minutes)
Measured: During the entire length of the operation
Operation Outcome - intraoperative blood loss
intraoperative blood loss (milliliters)
Measured: During the entire length of the operation
Operation Outcome - intraoperative complications
intraoperative complications (percentage)
Measured: During the entire length of the operation
Operation Outcome - conversion rate
conversion rate (percentage)
Measured: During the entire length of the operation
Operation Outcome - completeness of resection
completeness of resection (percentage)
Measured: During the entire length of the operation
Operation Outcome - lymph node yield
lymph node yield (number)
Measured: During the entire length of the operation
Secondary outcomes (1)
Adverse Event and Serious Adverse Event
Any postoperative complications (e.g. anastomotic or duodenal stump leakage, pneumonia, abdominal abscess, chyle leakage, ileus, wound infection), length of stay (days) on the intensive care unit (ICU) and in the hospital, and postoperative mortality (within 30 and 90 days after surgery).
Measured: within 30 and 90 days after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2026
- Study start1 Apr 2021
- Primary completion31 Mar 2031 (estimated)
- Study completion31 Mar 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric Cancer (Diagnosis)Studies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Other
- Enrolment
- 200 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, CHAN SHANNON MELISSA, Chinese University of Hong Kong
- Investigators
- Shannon Melissa CHAN, MBChB, FRCSEd, FHKAM (Surgery), Principal investigator, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07517432
- Sponsor's protocol ID
- 2021.043
- Status last verified
- Mar 2026
- First submitted
- 23 Mar 2026
- Last updated
- 8 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The UGIRA International Registry for Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) for Gastric Cancer
- ClinicalTrials.gov ID
- NCT07517432
- Acronym / sponsor ID
- 2021.043
- Conditions
- Gastric Cancer (Diagnosis), Gastrectomy
- Keywords
- gastric cancer, Gastrectomy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Study start
- 1 Apr 2021 (actual)
- Primary completion
- 31 Mar 2031 (estimated)
- Study completion
- 31 Mar 2031 (estimated)
- First posted
- 8 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Minimally invasive gastrectomy (MIG) has gained in popularity, since it is feasible, safe and oncologically comparable to open gastrectomy, while morbidity and duration of hospitalization are reduced, quality of life is increased, and conversion rate is low.
However, several challenges are faced during MIG, such as impaired depth perception and limited range of motion of instrument tips. Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) can potentially overcome these challenges, while providing comparable results regarding safety, technical feasibility, morbidity and oncological effectiveness. However, the techniques and outcomes of RAMIG vary in literature, which can partly be explained by lack of uniform definitions of postoperative outcomes that would allow international comparison. Furthermore, RAMIG is technically demanding and therefore associated with a learning curve.
To facilitate safe and effective implementation of RAMIG worldwide, the learning curve for RAMIG-procedures must be evaluated in detail. A prospective international registry with uniform data collection regarding surgical techniques and postoperative outcomes can provide a platform for multicontinental studies and the monitoring of surgical quality for surgeons who are implementing RAMIG in their center. Therefore, the aim of this study proposal is to expand the Upper Gastrointestinal International Robotic Association (UGIRA) collaboration by creating the UGIRA International Registry for RAMIG. The UGIRA network extends worldwide with members in Europe, Asia, North-America and South-America, therefore representing large-scale practice of RAMIG. The initial specific aims of the registry are to gain insight in surgical techniques and postoperative outcomes of RAMIG worldwide, and to evaluate the learning curve for RAMIG.
Data for this registry is collected prospectively and retrospectively.
Detailed description
Gastric cancer is the 3rd most common cause of cancer related deaths worldwide. For resectable gastric cancer, gastrectomy with curative intent combined with an adequate lymphadenectomy results in a 5-year survival rate of 10 - 30%. Survival can be improved by neoadjuvant or perioperative chemotherapy (FLOT-regimen) due to tumor volume reduction resulting in a higher R0-resection rate and due to targeting of (micro)metastases. Although a traditional open approach for gastrectomy is widely performed and provides adequate oncological results, minimally invasive gastrectomy (MIG) is increasingly implemented over the recent years. The aim of MIG is to minimize surgical trauma while achieving non-inferior oncological results and to reduce morbidity in comparison to open gastrectomy (OG).
Meta-analyses have demonstrated decreased postoperative pain, shorter duration of hospitalization, and improved postoperative recovery and quality of life in favour of MIG compared to OG. MIG reduces wound complications and overall complication rate, although no significant difference was found in complication rates for anastomotic leakage or stenosis, ileus, postoperative bleeding, abdominal abscess and postoperative mortality. The number of retrieved lymph nodes, resection radicality and disease free and overall survival are comparable between MIG and OG, although not many studies reported on these outcomes. Even with the operating time for MIG is prolonged by 45 - 49 minutes, intraoperative blood loss is reduced, and the conversion rate is low, these results show that MIG is feasible, safe and oncological comparable to OG. Morbidity and hospital stay are reduced and quality of life increased as well.
Although it has gained in popularity, MIG involves technical challenges such as impaired depth perception, limited range of motion of instruments and an ergonomically suboptimal posture of the surgeon while operating. Robotic assisted surgery can potentially overcome these challenges since it allows for improved dexterity by 3D-visualization for adequate depth perception and by greater range of motion using EndoWrist (Intuitive Surgical, Sunnyvale, CA, USA) with 7° of freedom, 90° articulation and 540° rotation, mimicking articulation of wrist and hand. Furthermore, tremor suppression, 10-fold enlargement and tool handling controlled by the primary surgeon instead of a secondary assisting surgeon contribute to an improved image stability and smooth movements.
These adjustments optimize surgical precision and facilitate anastomotic techniques and suturing. Robot-assisted minimally invasive gastrectomy (RAMIG) is comparable to MIG regarding safety, technical feasibility, intra- and postoperative morbidity and oncological effectiveness. Some studies suggest RAMIG could achieve a more extensive lymphadenectomy and less intraoperative blood loss, although it may prolong operating time and increase costs in comparison to MIG. However, RAMIG is a demanding proficiency for which training is required to acquire adequate robotic skills. While the learning curve for MIG is around 50 - 60 cases, surgeons experienced in MIG may reach proficiency for RAMIG after only 20 - 25 cases. Since complications rates may be higher for surgeons starting with RAMIG, the duration of the learning period should be minimized in order to prevent unnecessary patient harm. However, most studies are retrospective, single-centered, have limited power due to small sample size, and contain heterogeneity in anastomotic techniques and the extent of lymph node dissection. An unknown learning curve may worry surgeons and could restrain them from implementing RAMIG in their hospitals. Therefore, additional research is warranted to investigate this learning period in detail.
Variation in definitions of complications after gastrectomy lead to differences in reported outcomes, which represents a major challenge when comparing results from multiple centers. Uniform definitions should be used in order to adequately compare complications and their impact on outcomes internationally, which could aid in identifying factors in clinical care which could be improved. Currently, there is no widespread consensus on standardized definitions of complications after gastrectomy. Therefore, the Gastrectomy Complications Consensus Group (GCCG) was formed. Standardize definitions have yet to be published. However, an international registry using an online electronic case report form (eCRF) to uniformly collect perioperative outcomes is essential to minimize such variability. Therefore, this study aims to establish such an international RAMIG registry.
The current initiative aims to expand the collaboration of international experts that was previously established with UGIRA by creating a registry for RAMIG that can be used to initiate international studies and to monitor the surgical quality for surgeons implementing RAMIG in new centers. The UGIRA aims to facilitate the effective implementation and furtherance of robotic esophagogastric surgery. In this context, UGIRA already initiated an international registry for RAMIE and defined a structured training pathway that can be used to guide surgeons starting with RAMIE through their implementation phase. With a more intensified collaboration that also focuses on RAMIG, UGIRA aims to facilitate its worldwide implementation and advancement, and to provide an international platform for discussion and to share surgical vision on topics in this area. This existing experience and UGIRA-network can be used to achieve the key initial aims of the RAMIG registry, which are to create an international registry to gain insight in surgical techniques and postoperative outcomes of RAMIG worldwide, and to evaluate the learning curve for RAMIG.
The principal investigators have previously established an international registry for robot-assisted minimally invasive esophagectomy (RAMIE) supported by Intuitive Surgical Inc. In the context of aiming for worldwide collaboration between international experts in robotic esophagogastric surgery, the UMC Utrecht has co-founded the Upper Gastrointestinal International Robotic Association (UGIRA, www.ugira.org), currently chaired by Richard van Hillegersberg. The UGIRA now includes members from Europe, Asia, North- America and South America (Annex 1), and aims to facilitate the effective implementation and furtherance of robotic esophagogastric surgery.
In the UMC Utrecht, the investigators have developed a structured training pathway that can be used to guide surgeons starting with RAMIE through their implementation phase. It is found that applying this structured training pathway can reduce the learning curve for RAMIE substantially from 70 to 24 cases. Furthermore, no differences were observed regarding postoperative morbidity, mortality and oncological outcomes during the learning phase compared to after completing the learning phase.
Based on these studies, it can be concluded that the structured training pathway is a safe and effective strategy to implement RAMIE in new centers. UGIRA is currently working on establishing a structured training pathway for RAMIG, as was previously done for RAMIE.
Data for this registry is collected prospectively and retrospectively.
Study design
- Observational model
- Case only
- Time perspective
- Other
- Target follow-up
- 10 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| All patients undergoing Robot-Assisted Minimally Invasive Gastrectomy. | – | –All patients with gastric cancer, who is about to undergo Robot-Assisted Minimally Invasive Gastrectomy. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All gastric cancer patients undergoing RAMIG in a center
Key inclusion criteria (1 listed)
- All gastric cancer patients undergoing RAMIG in a center
Key exclusion criteria (1 listed)
- No
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Operation Outcome - operating time
Time frame: During the entire length of the operation
Operating time (minutes)
Operation Outcome - intraoperative blood loss
Time frame: During the entire length of the operation
intraoperative blood loss (milliliters)
Operation Outcome - intraoperative complications
Time frame: During the entire length of the operation
intraoperative complications (percentage)
Operation Outcome - conversion rate
Time frame: During the entire length of the operation
conversion rate (percentage)
Operation Outcome - completeness of resection
Time frame: During the entire length of the operation
completeness of resection (percentage)
Operation Outcome - lymph node yield
Time frame: During the entire length of the operation
lymph node yield (number)
1 secondary outcome
Adverse Event and Serious Adverse Event
Time frame: within 30 and 90 days after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Gastric Cancer (Diagnosis)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Shannon Melissa CHAN, MBChB, FRCSEd, FHKAM (Surgery) contact
Shannon Melissa CHAN, MBChB, FRCSEd, FHKAM (Surgery) principal investigator
Chinese University of Hong Kong
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastric Cancer (Diagnosis) and Gastrectomy, run by Chinese University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shannon Melissa CHAN, MBChB, FRCSEd, FHKAM (Surgery) (+852 3505 2956, shannonchan@surgery.cuhk.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Operation Outcome - operating time (time frame: During the entire length of the operation). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2026.